Company description

ANAB (AnaptysBio, Inc.) is a clinical-stage biotechnology company that focuses on developing antibody-based therapeutics to address unmet medical needs in severe inflammatory diseases and cancer. The company's proprietary platform technology, called somatic hypermutation (SHM), allows for the discovery of highly specific and potent antibodies against disease targets. ANAB's pipeline includes potential treatments for various autoimmune disorders, such as atopic dermatitis and eosinophilic asthma, as well as immune-mediated cancers like non-small cell lung cancer and metastatic melanoma. The company is committed to advancing these potential treatments through rigorous clinical trials, with collaboration from major pharmaceutical companies and prestigious research institutions. With its innovative technology and promising pipeline, ANAB is poised to become a leader in the development of novel antibody therapeutics.